CytoGam Acquisition Strengthens ZLB Behring's Immunoglobulin Portfolio
This article was originally published in The Pink Sheet Daily
Executive Summary
MedImmune divests the transplantation treatment to ZLB Behring for an up-front payment of $50 mil.